Paris - Delayed Quote EUR

Sensorion SA (ALSEN.PA)

Compare
0.7300 0.0000 (0.00%)
At close: October 18 at 5:35 PM GMT+2

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Ms. Nawal Ouzren CEO & Director -- -- 1978
Ms. Laurene Danon Chief Financial Officer -- -- --
Mr. Bernd Schmidt Chief Technical Officer -- -- --
Dr. Geraldine Honnet M.D. Chief Medical Officer -- -- --
Ms. Christine Le Bec Head of CMC Gene Therapy -- -- --
Ms. Stephanie Filipe Head of the Project Management Office -- -- --
Mr. Laurent Desire Head of Preclinical Development -- -- --
Rachel Cooper Head of Audiology -- -- --

Sensorion SA

375, rue du Professeur Joseph Blayac
Montpellier, 34080
France
33 4 67 20 77 30 https://www.sensorion.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
61

Description

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 clinical trial for the treatment of hearing preservation after cochlear implantation. It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene. The company was incorporated in 2009 and is headquartered in Montpellier, France.

Corporate Governance

Sensorion SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

September 18, 2024 at 5:30 AM UTC

Sensorion SA Earnings Date

Recent Events

Related Tickers